IL18 and Alzheimer disease: Herein, JDYZF reduced the expression levels of IL-1β and IL-18 in multiple AD rat tissues, reduced the inflammatory response, and weakened the effect of inflammatory factors on the vicious cycle of Aβ production and pyroptosis.